后新冠功能障碍性呼吸患者前瞻性病例系列:症状、生活质量及客观呼吸标志物的演变
Evolution of symptoms, quality of life, and objective breathing markers in a prospective case series of patients with post-COVID-19 dysfunctional breathing
本前瞻性病例系列纳入48名确诊为后新冠功能障碍性呼吸(DB)的患者,随访6-9个月。结果显示基线Nijmegen评分≥23的患者比例由68%降至43%(p=0.02),呼吸困难MmRC分级中2至4级患者比例显著下降,生活质量及功能状态有所改善。尽管客观CPET指标如过度通气及呼吸参数离散度等得到改善,47%的患者仍存在显著功能受限。
- Article
- Open access
- Published: 06 October 2026
- Léon Genecand ORCID: orcid.org/0000-0001-6965-04801,2,3,
- Isabelle Frésard1,
- Marco Altarelli1,
- Alzbeta Binkova1,
- Stéphanie Vaudan1,4,
- Arnaud Rapillard1,
- Antoine Beurnier5,6,7,
- David Montani5,6,7,
- Cyril Jaksic8 &
- …
- Pierre-Olivier Bridevaux ORCID: orcid.org/0000-0002-8021-09501,2,3
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Dysfunctional breathing (DB) was described after coronavirus disease 2019 (COVID-19) and can contribute to persistent dyspnoea and other associated symptoms but the evolution of DB after COVID-19 is poorly described. Individuals with persistent symptoms after COVID-19 were evaluated and those diagnosed with DB were included. DB was diagnosed by identifying an abnormal breathing pattern during cardiopulmonary exercise testing (CPET) associated with compatible symptoms after ruling out cardiopulmonary conditions that could account for the symptoms. All included patients were prospectively followed and systematically assessed 6–9 months after their diagnosis. Given the multiplicity of analyses and the absence of a pre-specified primary analysis, all findings should be considered exploratory and hypothesis-generating. Forty-eight patients were included and 45 patients were successfully reassessed at 6–9 months. Forty-two received specific respiratory physiotherapy targeting DB. The proportion of individuals with a Nijmegen score ≥ 23 decreased from 30 (68%) at baseline to 19 (43%) at follow-up (p = 0.02). Dyspnea improved at 6–9 months, with 0%, 11%, 44%, 35%, and 11% of patients presenting mMRC grades 0, 1, 2, 3, and 4 at baseline, compared with 20%, 39%, 37%, 4%, and 0% at follow-up (p < 0.001). Improvements in quality of life and functional status were observed. However, 21 patients (47%) continued to experience significant functional limitations, defined as a post-COVID-19 functional status (PCFS) scale score ≥ 2. Objective markers of DB during CPET improved, with reductions in hyperventilation, dispersion of breathing parameters, and the number of sighs. In most patients diagnosed with DB after COVID-19, improvements in symptoms, QoL, functional status and objective markers of DB were observed at 6–9 months. A substantial proportion of patients remained disabled.
Acknowledgements
We thank all patients who participated in this cohort. We thank the Ligue Pulmonaire Genevoise, the Ligue Pulmonaire Valaisanne and the foundation Lancardis for their financial support to develop and adapt methods to measure the dispersion, sighs and entropy during exercise testing34–36.
Funding
This study did not receive any specific grants from public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Service de Pneumologie, Centre Hospitalier du Valais Romand, Sion, Switzerland
Léon Genecand, Isabelle Frésard, Marco Altarelli, Alzbeta Binkova, Stéphanie Vaudan, Arnaud Rapillard & Pierre-Olivier Bridevaux
Faculty of Medicine, University of Geneva, Geneva, Switzerland
Léon Genecand & Pierre-Olivier Bridevaux
Service de Pneumologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
Léon Genecand & Pierre-Olivier Bridevaux
Service de Physiothérapie, Centre Hospitalier du Valais Romand, Martigny, Switzerland
Stéphanie Vaudan
Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, FHU Cournand, ERN Lung, Hôpital Bicêtre, Le Kremlin Bicêtre, France
Antoine Beurnier & David Montani
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
Antoine Beurnier & David Montani
INSERM UMR_S 1358 HPPIT Pulmonary hypertension: pathophysiology and novel therapies, Marie Lannelongue Hospital and Bicêtre Hospital, Le Kremlin-Bicêtre, France
Antoine Beurnier & David Montani
Centre de Recherche Clinique, hôpitaux Universitaires de Genève, Geneva, Switzerland
Cyril Jaksic
Authors
- Léon Genecand
- Isabelle Frésard
- Marco Altarelli
- Alzbeta Binkova
- Stéphanie Vaudan
- Arnaud Rapillard
- Antoine Beurnier
- David Montani
- Cyril Jaksic
- Pierre-Olivier Bridevaux
Corresponding author
Correspondence to Léon Genecand.
Ethics declarations
Competing interests
The authors have no competing interests.
Informed consent
Patients were involved in the design of the study as discussed previously16.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Genecand, L., Frésard, I., Altarelli, M. et al. Evolution of symptoms, quality of life, and objective breathing markers in a prospective case series of patients with post-COVID-19 dysfunctional breathing. Sci Rep (2026). https://doi.org/10.1038/s41598-026-72712-7
Received: 21 May 2026
Accepted: 17 September 2026
Published: 06 October 2026
DOI: https://doi.org/10.1038/s41598-026-72712-7
Keywords
来源:Nature 健康护理主题 · nature.com